Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Quetiapine XR monotherapy versus augmentation with SSRI/venlafaxine or lithium in treatment-resistant depression
2008-000908-91Phase 3Completed
- Sponsor
- AstraZeneca
- Start
- Jul 2008
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of quetiapine, lithium carbonate and venlafaxine in treatment-resistant depression (TRD) and major depressive disorder (MDD) (3 arms), sponsored by AstraZeneca. Primary endpoint: Change in MADRS total score from randomization to week 6. Started Jul 2008; status: completed.
02
Drugs
quetiapinelithium carbonatevenlafaxine
03
Conditions
treatment-resistant depression (TRD)major depressive disorder (MDD)
Beyond the preview
Go deeper on 2008-000908-91.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-000908-91.